| |
GOL
|
PBO-NE
|
PBO-EE
|
|---|
|
Number of patients
|
287
|
99
|
50
|
|
Female (%)
|
231 (0.8)
|
72 (0.73)
|
41 (0.82)
|
|
Age (SD)
|
51.92 (11.94)
|
52.77 (11.17)
|
49.24 (11.84)
|
|
Disease duration (SD)
|
7.19 (6.82)
|
7.64 (8.16)
|
6.56 (6.06)
|
|
BMI (SD)
|
27.19 (5.74)
|
26.88 (5.36)
|
26.73 (6.65)
|
|
Initial DAS (SD)
|
5.97 (0.81)
|
5.87 (1.02)
|
5.93 (0.8)
|
|
RF positive (%)
|
265 (0.92)
|
91 (0.92)
|
45 (0.9)
|
|
ACPA positive (%)
|
262 (0.91)
|
92 (0.93)
|
48 (0.96)
|
|
Number of visits (SD)
|
15.03 (2.7)
|
14.65 (3.18)
|
15.76 (0.72)
|
|
Number removed (%) a
|
5 (2)
|
10 (10)
|
0 (0)
|
- GOL includes patients randomized to GOL treatment at week 0. PBO-NE includes patients randomized to PBO at week 0 who did not qualify for the early escape protocol. PBO-EE includes patients randomized to PBO at week 0 who qualified for the early escape protocol
-
ACPA anti-citrulinated peptide antibody, BMI body mass index, DAS Disease Activity Score, EE early escape, GOL golimumab, NE non-early escape, PBO placebo, RF rheumatoid factor, SD standard deviation
-
aPatients from any arm who dropped out within 4 weeks of initial GOL treatment were removed from analyses
